KFF September 6, 2024
Matt McGough, Justin Lo, Delaney Tevis, Matthew Rae, Cynthia Cox

More than two in five (42%) or 57.4 million adults under 65 with private insurance could be eligible under clinical criteria for GLP-1 drugs used to treat people with type 2 diabetes, obesity, or excess weight and weight-related health issues, according to a new KFF analysis.

Though only about 3% of adults with employer coverage had a prescription in 2022, demand for and spending on GLP-1 drugs has grown and could...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Insurance, Patient / Consumer, Payer, Pharma / Biotech, Survey / Study, Trends
Shifting Our Healthcare Delivery Model from Reactive to Proactive
Medtronic, Tempus testing AI to find potential TAVR patients
Why Tufts Medicine ended its hospital-at-home program
How the Triadic Model of Interpreter, Patient and Provider has Elevated Healthcare Communications
Is a lack of understanding driving alcohol-related deaths in the U.S.?

Share This Article